Skip to content
Biodatica
Start free

Regeneron Pharmaceuticals

Orange, California

OncologyFiled/ApprovedListed · REGN

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Study registered, no phase assigned: A Study to Identify and Characterize Adults and Pediatric Participants With Cat and/or Birch Allergy

yesterdayTrial registeredJul 17, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Momentum 100 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Filed/Approved

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1/PHASE2 registered

    Aug 31, 2026

    High-Grade Glioma (HGG), Posterior Fossa-A Ependymoma · NOT_YET_RECRUITING · sponsor: Regeneron Pharmaceuticals · A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma

    ClinicalTrials.gov · NCT07567469 (opens the source filing in a new tab)

  2. Trial

    Study registered

    Aug 17, 2026

    Conjunctivitis Allergic · NOT_YET_RECRUITING · sponsor: Regeneron Pharmaceuticals · A Study to Identify and Characterize Adults and Pediatric Participants With Cat and/or Birch Allergy

    ClinicalTrials.gov · NCT07710846 (opens the source filing in a new tab)

  3. Trial

    PHASE3 registered

    Mar 9, 2026

    Cancer-Associated Thrombosis (CAT) · RECRUITING · sponsor: Regeneron Pharmaceuticals · REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis

    ClinicalTrials.gov · NCT07410117 (opens the source filing in a new tab)

  4. Trial

    PHASE2 registered

    Nov 18, 2024

    Non-Small Cell Lung Cancer · RECRUITING · sponsor: Regeneron Pharmaceuticals · A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

    ClinicalTrials.gov · NCT06465329 (opens the source filing in a new tab)

  5. Trial

    PHASE1/PHASE2 registered

    Sep 23, 2024

    Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors · RECRUITING · sponsor: Regeneron Pharmaceuticals · A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

    ClinicalTrials.gov · NCT06413680 (opens the source filing in a new tab)

  6. Trial

    PHASE1/PHASE2 registered

    Dec 19, 2023

    Multiple Myeloma · RECRUITING · sponsor: Regeneron Pharmaceuticals · A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

    ClinicalTrials.gov · NCT05828511 (opens the source filing in a new tab)

  7. Trial

    PHASE3 registered

    Dec 13, 2023

    Diffuse Large B-cell Lymphoma (DLBCL) · RECRUITING · sponsor: Regeneron Pharmaceuticals · A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

    ClinicalTrials.gov · NCT06091865 (opens the source filing in a new tab)

  8. Trial

    PHASE1 registered

    Feb 7, 2023

    Advanced Solid Tumor, Metastatic Solid Tumor · RECRUITING · sponsor: Regeneron Pharmaceuticals · A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab

    ClinicalTrials.gov · NCT05259709 (opens the source filing in a new tab)

  9. Trial

    PHASE4 registered

    Jan 11, 2023

    Moderate-to-Severe Atopic Dermatitis, Atopic Eczema · COMPLETED · sponsor: Regeneron Pharmaceuticals · Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial

    ClinicalTrials.gov · NCT05590585 (opens the source filing in a new tab)

  10. Trial

    Study registered

    Oct 26, 2022

    Non-small Cell Lung Cancer · RECRUITING · sponsor: Regeneron Pharmaceuticals · An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe

    ClinicalTrials.gov · NCT05363319 (opens the source filing in a new tab)

  11. Trial

    PHASE3 registered

    Oct 6, 2022

    Paroxysmal Nocturnal Hemoglobinuria · TERMINATED · sponsor: Regeneron Pharmaceuticals · Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria

    ClinicalTrials.gov · NCT05131204 (opens the source filing in a new tab)

  12. Trial

    PHASE1 registered

    Oct 5, 2020

    Squamous Cell Carcinoma of Head and Neck · TERMINATED · sponsor: Regeneron Pharmaceuticals · Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies

    ClinicalTrials.gov · NCT04465487 (opens the source filing in a new tab)

  13. Trial

    Study registered

    Jun 27, 2019

    Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma · COMPLETED · sponsor: Regeneron Pharmaceuticals · CemiplimAb Survivorship Epidemiology

    ClinicalTrials.gov · NCT03836105 (opens the source filing in a new tab)

  14. Trial

    PHASE1 registered

    Apr 11, 2019

    Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma · COMPLETED · sponsor: Regeneron Pharmaceuticals · Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma

    ClinicalTrials.gov · NCT03889912 (opens the source filing in a new tab)

  15. Trial

    PHASE3 registered

    Oct 15, 2015

    Atopic Dermatitis · ACTIVE_NOT_RECRUITING · sponsor: Regeneron Pharmaceuticals · Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)

    ClinicalTrials.gov · NCT02612454 (opens the source filing in a new tab)

  16. Trial

    PHASE1 registered

    Jan 9, 2015

    Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia · COMPLETED · sponsor: Regeneron Pharmaceuticals · Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

    ClinicalTrials.gov · NCT02290951 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources